ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARVN vs CTMX // EV/EBITDA & P/E VALUATION

Arvinas Inc. (NASDAQ) VS. CytomX Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ARVN 4 — CTMX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARVN VS. CTMX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARVN CTMX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.10% -20.50% -11.60 CTMX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -15.19% — TIE /fcf-yield <GO>
Operating Margin -45.10% -29.30% -15.80 CTMX /operating-margins <GO>
Net Profit Margin -30.80% -22.80% -8.00 CTMX /net-margins <GO>
Revenue Growth (YoY) -0.30% -44.80% +44.50 ARVN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 ARVN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.4 43.5 +10.90 ARVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $513.9M $509.9M $4.1M ARVN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARVN REV CTMX REV ARVN GROSS % CTMX GROSS % ARVN FCF CTMX FCF
FY 2025 $262.6M $76.2M — — -$275.7M -$75.8M
FY 2024 $263.4M $138.1M — — -$261.1M -$86.5M
FY 2023 $78.5M $101.2M — — -$347.8M -$56.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARVN // BETA —
CTMX // BETA —